These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 7692468)

  • 1. [Inhibitor for protein-farnesylation].
    Takeshima H; Omura S
    Tanpakushitsu Kakusan Koso; 1993 Aug; 38(11):1695-703. PubMed ID: 7692468
    [No Abstract]   [Full Text] [Related]  

  • 2. NMR studies of novel inhibitors bound to farnesyl-protein transferase.
    Koblan KS; Culberson JC; Desolms SJ; Giuliani EA; Mosser SD; Omer CA; Pitzenberger SM; Bogusky MJ
    Protein Sci; 1995 Apr; 4(4):681-8. PubMed ID: 7613466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
    Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ras farnesyltransferase: a new therapeutic target.
    Leonard DM
    J Med Chem; 1997 Sep; 40(19):2971-90. PubMed ID: 9301658
    [No Abstract]   [Full Text] [Related]  

  • 5. [Inhibitors of Ras farnesylation: tomorrow's anticancer agents?].
    Perrin D; Halazy S; Hill B
    Bull Cancer; 1997 Jun; 84(6):635-42. PubMed ID: 9295868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
    Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
    Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
    Lerner EC; Hamilton AD; Sebti SM
    Anticancer Drug Des; 1997 Jun; 12(4):229-38. PubMed ID: 9199657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudopeptide inhibitors of Ras farnesyl-protein transferase.
    Graham SL; deSolms SJ; Giuliani EA; Kohl NE; Mosser SD; Oliff AI; Pompliano DL; Rands E; Breslin MJ; Deana AA
    J Med Chem; 1994 Mar; 37(6):725-32. PubMed ID: 8145221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
    Qian Y; Vogt A; Sebti SM; Hamilton AD
    J Med Chem; 1996 Jan; 39(1):217-23. PubMed ID: 8568811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of farnesyl-protein transferase by gliotoxin and acetylgliotoxin.
    Van der Pyl D; Inokoshi J; Shiomi K; Yang H; Takeshima H; Omura S
    J Antibiot (Tokyo); 1992 Nov; 45(11):1802-5. PubMed ID: 1281813
    [No Abstract]   [Full Text] [Related]  

  • 11. Substitution of cadmium for zinc in farnesyl:protein transferase alters its substrate specificity.
    Zhang FL; Fu HW; Casey PJ; Bishop WR
    Biochemistry; 1996 Jun; 35(25):8166-71. PubMed ID: 8679569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesylation of p21 Ras proteins in Xenopus oocytes.
    Zhao J; Kung HF; Manne V
    Cell Mol Biol Res; 1994; 40(4):313-21. PubMed ID: 7866432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
    Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
    Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase.
    Hunt JT; Lee VG; Leftheris K; Seizinger B; Carboni J; Mabus J; Ricca C; Yan N; Manne V
    J Med Chem; 1996 Jan; 39(2):353-8. PubMed ID: 8558502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells.
    James GL; Goldstein JL; Brown MS; Rawson TE; Somers TC; McDowell RS; Crowley CW; Lucas BK; Levinson AD; Marsters JC
    Science; 1993 Jun; 260(5116):1937-42. PubMed ID: 8316834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
    Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
    J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fluorescence assay for geranylgeranyl transferase type I.
    Pickett WC; Zhang FL; Silverstrim C; Schow SR; Wick MM; Kerwar SS
    Anal Biochem; 1995 Feb; 225(1):60-3. PubMed ID: 7778787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesylation and proteolysis are sequential, but distinct steps in the CaaX box modification pathway.
    Farh L; Mitchell DA; Deschenes RJ
    Arch Biochem Biophys; 1995 Apr; 318(1):113-21. PubMed ID: 7726551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of farnesyltransferase and Ras processing peptidase.
    Hall CC; Watkins JD; Ferguson SB; Foley LH; Georgopapadakou NH
    Biochem Biophys Res Commun; 1995 Dec; 217(3):728-32. PubMed ID: 8554591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.